Share This

Public company info - PuraPharm Corporation Ltd. , 01498.HK

Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

PuraPharm Corporation Ltd., 01498.HK - Cash Flow 2022-12 2021-12 2020-12 2019-12 2018-12 2017-12 2016-12 2015-12 2014-12 2013-12 2012-12
Net Cash Flow from Operating Activities 92,532 -10,033 129,606 133,873 81,403 -29,521 -46,837 -980 36,611 17,711 67,298
Net Cash Flow from Return on Investments & Servicing of Finance -23,708 -26,667 -32,716 -28,673 -22,903 -23,437 -28,557 -9,410 -12,350 -12,894 -10,878
 Interest Received 475 360 456 592 431 450 710 833 714 255 81
 Interest Paid -24,183 -27,027 -33,172 -29,265 -23,334 -18,945 -9,331 -10,243 -13,064 -13,149 -10,959
 Dividend Received 0 0 0 0 0 0 0 0 0 0 0
 Dividend Paid 0 0 0 0 0 -4,942 -19,936 0 0 0 0
 Others 0 0 0 0 0 0 0 0 0 0 0
Taxes (Paid) / Refunded -4,502 -4,847 -10,208 -3,265 -9,373 -13,681 -9,701 -12,423 -6,234 -6,932 -5,251
Net Cash Flow from Investing Activities -31,245 6,005 -92,110 -91,461 -36,088 -293,101 -65,208 -44,760 -24,634 -6,268 -37,793
 Additions to Fixed Assets -21,669 -3,093 -76,047 -94,945 -45,192 -101,628 -41,284 -28,415 -8,586 -17,187 -13,426
 Disposal of Fixed Assets 96 2,891 677 0 91 744 0 1,164 457 132 132
 Increase in Investments -1,204 0 0 -9,000 0 -171,293 0 -3,028 0 0 0
 Decrease in Investments 0 0 0 0 11,685 0 0 0 0 0 0
 Net Cash Flow with Related Parties 4,610 0 -15,000 15,000 30,000 0 0 0 0 -3,134 163
 Others -13,078 6,207 -1,740 -2,516 -32,672 -20,924 -23,924 -14,481 -16,505 13,921 -24,662
Net Cash Flow before Financing Activities 33,077 -35,542 -5,428 10,474 13,039 -359,740 -150,303 -67,573 -6,607 -8,383 13,376
Net Cash Flow from Financing Activities -11,411 10,992 29,559 -49,981 -4,690 228,066 131,968 278,040 12,805 15,504 13,124
 New Loans 343,046 374,882 407,188 333,417 514,214 604,034 426,568 327,765 286,323 351,552 304,339
 Loans Repayment -359,870 -363,890 -460,677 -398,037 -548,904 -375,968 -284,581 -364,652 -303,518 -332,914 -291,378
 Fixed Income/Debt Instruments 0 0 0 0 0 0 0 0 0 0 0
 Repayment of Fixed Income/Debt Instruments 0 0 0 0 0 0 0 0 0 0 0
 Equity Financing 803 0 98,048 0 0 0 0 314,927 0 0 0
 Net Cash Flow with Related Parties 4,610 0 -15,000 15,000 30,000 0 0 0 0 -3,134 163
 Others 0 0 0 -361 0 0 -10,019 0 30,000 0 0
Increase(Decrease) in Cash & Cash Equivalents 21,666 -24,550 24,131 -39,507 8,349 -131,674 -18,335 210,467 6,198 7,121 26,500
Cash & Cash Equivalents at Beginning of Year 59,671 75,810 50,429 90,516 86,805 209,129 232,243 30,675 25,039 16,870 -9,482
Net Cash Flow due to Change in Exchange Rate/Others -5,506 6,248 1,250 -580 -4,638 9,350 -4,779 -8,899 -562 1,048 -148
Cash & Cash Equivalents at End of Year 75,831 57,508 75,810 50,429 90,516 86,805 209,129 232,243 30,675 25,039 16,870
Currency Hong Kong Dollar Hong Kong Dollar Hong Kong Dollar Hong Kong Dollar Hong Kong Dollar Hong Kong Dollar Hong Kong Dollar Hong Kong Dollar Hong Kong Dollar Hong Kong Dollar Hong Kong Dollar
Unit
Auditor's Opinion 0 1 1 1 1 1 1 1 0 0 0

Notes:1–Unqualified; 2–Unqualified ( not qualified in respect of fundamental uncertainly because of proper disclosure); 3–Qualified

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.